The Impact of Biosimilars in Canada

The Impact of Biosimilars in Canada 2018.png

The Impact of Biosimilars in Canada

CARE ™ Faculty members Dr. John Marshall (McMaster University), Dr. Brian Feagan (Western University) and Karen Voin (Vice President of the Canadian Life and Health Insurance Association) met in July 2018 to discuss biosimilars in Canada. 

This publication on the Impact of Biosimilars in Canada focuses on a physician’s and payer’s perspective and includes discussion on the following:

  • Major biosimilar updates that have happened since CARE™’s last video discussion

  • The evolution in stakeholder attitude towards biosimilars in clinical practice

  • The challenges proposed by biosimilar adoption (pharmacovigilance)

  • The difference in biosimilar opinion from one specialty group to another (e.g. oncology versus hematology)   

  • The challenges of tracking biosimilars and possible ways to overcome those challenges

  • Factors that limit biosimilar adoption in Canada

  • The potential benefits of biosimilar associated cost savings

The CARE™ Faculty has produced a number of outputs on the subject on biosimilars including numerous video clips and publications.

For a recent publication titled “Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching” co-authored by CARE™ Faculty member Dr. Brian Feagan, and published in the Applied Health Economics and Health Policy Journal, click here:  https://link.springer.com/article/10.1007/s40258-018-0371-0

Contributing Faculty

________

Dr. John Marshall, MD
McMaster University

Dr. Brian Feagan, MD
Western University

Karen Voin
Vice President of the Canadian Life and Health Insurance Association